154 related articles for article (PubMed ID: 38732050)
1. Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors.
Climent E; González-Guerrero A; Marco-Benedí V; García-Andreu MD; Mediavilla-García JD; Suárez-Tembra M; Benaiges D; Pintó X; Pedro-Botet J
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732050
[TBL] [Abstract][Full Text] [Related]
2. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
[TBL] [Abstract][Full Text] [Related]
3. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
[TBL] [Abstract][Full Text] [Related]
4. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
Carmena R; Lussier-Cacan S; Roy M; Minnich A; Lingenhel A; Kronenberg F; Davignon J
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):129-36. PubMed ID: 8548413
[TBL] [Abstract][Full Text] [Related]
5. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
6. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
8. Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia.
Martinez M; Brodlie S; Griesemer A; Kato T; Harren P; Gordon B; Parker T; Levine D; Tyberg T; Starc T; Cho I; Min J; Elmore K; Lobritto S; Hudgins LC
Am J Cardiol; 2016 Aug; 118(4):504-10. PubMed ID: 27365335
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
Vuorio A; Watts GF; Kovanen PT
Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
[TBL] [Abstract][Full Text] [Related]
11. Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia.
Vlahos AP; Naka KK; Bechlioulis A; Theoharis P; Vakalis K; Moutzouri E; Miltiadous G; Michalis LK; Siamopoulou-Mavridou A; Elisaf M; Milionis HJ
Pediatr Cardiol; 2014 Jan; 35(1):63-70. PubMed ID: 23821294
[TBL] [Abstract][Full Text] [Related]
12. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
14. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
17. Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
Mangili LC; Miname MH; Silva PRS; Bittencourt MS; Rocha VZ; Mangili OC; Salgado Filho W; Chacra AP; Jannes CE; Pereira AC; Santos RD
Atherosclerosis; 2017 Aug; 263():393-397. PubMed ID: 28499609
[TBL] [Abstract][Full Text] [Related]
18. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
19. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.
Gandelman K; Glue P; Laskey R; Jones J; LaBadie R; Ose L
Pediatr Cardiol; 2011 Apr; 32(4):433-41. PubMed ID: 21259004
[TBL] [Abstract][Full Text] [Related]
20. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia.
Ogura M; Hori M; Harada-Shiba M
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):181-8. PubMed ID: 26543100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
